AAP
SGMO

Arax Advisory Partners’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Arax Advisory Partners’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-31
Closed -$20 – 4480
2025
Q3 		$20 Buy
+31
New +$17 ﹤0.01% 3575
2024
Q4 		– Sell
-142
Closed -$123 – 2711
2024
Q3 		$123 Hold
142
– – ﹤0.01% 2546
2024
Q2 		$51 Buy
+142
New +$77 ﹤0.01% 2515

Other funds holding SGMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Arax Advisory Partners's SGMO Position: Q4 2025 in Review

Arax Advisory Partners sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2025, closing a stake of 31 shares — an estimated $20 sold.

Arax Advisory Partners first reported a position in SGMO in Q2 2024 and held it in 3 quarters. The position peaked at $123 in Q3 2024. 105 funds tracked by Wall St. Rank hold SGMO as of Q4 2025.

  • Arax Advisory Partners reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2025 after selling out during the quarter.
  • Arax Advisory Partners sold 31 SANGAMO THERAPEUTICS INC shares in Q4 2025, an estimated $20.
  • Arax Advisory Partners first reported a position in SANGAMO THERAPEUTICS INC in Q2 2024 and held it in 3 quarters.
  • Arax Advisory Partners's SANGAMO THERAPEUTICS INC position peaked at $123 in Q3 2024.
  • 105 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2025.

Based on Arax Advisory Partners's 13F filing for Q4 2025, filed 13 Feb 2026.